Clin Cancer Res: Efficacy of Phase 3 Levatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

In a phase 3 SELECT study in many countries, Lenvatinib showed an effective treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC); however, lenvatinib was used in RR-DTC patients in China The efficacy of in has not been verified
.
Data in recent years indicate that there are approximately 194,000 confirmed thyroid cancer patients in China

This study aims to evaluate the efficacy and safety of lenvatinib in Chinese patients with RR-DTC
.

Chinese patients (n=151) diagnosed with RR-DTC were recruited and randomly divided into two groups at a 2:1 ratio, receiving levatinib (24 mg/day, n=103) or placebo (n=48) ) Treatment, every 28 days is a course of treatment
.
The primary endpoint is progression-free survival (PFS); key secondary endpoints include objective response rate and safety

Progression-free survival of the two groups of patients

The progression-free survival of the lenvatinib group was significantly longer than that of the placebo group (median PFS: 23.
9 vs 3.
7 months; hazard ratio [HR] 0.
16, 95%CI 0.
10-0.
26; p<0.
0001)
.
The objective response rates of the lenvatinib group and the placebo group were 69.

In summary, compared with placebo, lenvatinib (24 mg/day) can also significantly improve the progression-free survival and objective remission rate of Chinese RR-DTC patients
.
There is no new or unexpected toxicity

Xiangqian Zheng, et al.